NACA2

Across TCGA pan-cancer cohorts, NACA2 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated NACA2 data layer compared with 1 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NACA2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NACA2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and COAD show a favorable association.

LIHC, SKCM, and LUAD are the cancer types where NACA2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.409	0.612	<.001	82	view →
SKCM	OS	Median	All	0.839	0.723	<.001	48	view →
LUAD	OS	Median	All	0.761	0.860	.002	40	view →
KICH	DFS	Median	III,IV	0.373	1.000	.008	31	view →
COAD	DFS	Quartile	All	0.739	0.513	.011	29	view →
ESCA	DFS	Quartile	All	0.386	0.615	.011	21	view →
ACC	OS	Quartile	All	0.637	0.911	.009	21	view →
MESO	DFS	Quartile	All	0.795	0.153	.006	18	view →
CHOL	DFS	Quartile	All	0.632	0.115	.001	16	view →
THCA	OS	Tertile	II,III,IV	0.927	0.727	.014	15	view →
BLCA	DFS	Tertile	II,III,IV	0.620	0.463	.022	12	view →
OV	OS	Tertile	II,III,IV	0.299	0.397	.023	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

NACA2–LIHC (DFS)

Open the LIHC breakdown →